

Table 4.25

Cancer of the Female Breast (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2008-2012
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	293,300	99.4%	234,974	99.5%	31,773	99.3%	22,742	99.2%	1,207	99.3%	29,953	99.3%
Epidermoid carcinoma ^d (8051-8131)	145	0.0%	117	0.0%	21	0.1%	-	-	-	-	-	-
Adenocarcinoma ^e	287,384	97.4%	230,473	97.6%	30,801	96.3%	22,407	97.7%	1,181	97.1%	29,328	97.2%
Adenocarcinoma, NOS (8140)	2,176	0.7%	1,709	0.7%	296	0.9%	130	0.6%	-	-	229	0.8%
Infiltrating duct carcinoma (8500)	216,104	73.2%	171,202	72.5%	24,088	75.3%	17,955	78.3%	932	76.6%	22,451	74.4%
Lobular carcinoma, NOS (8520)	26,726	9.1%	22,815	9.7%	2,319	7.2%	1,289	5.6%	90	7.4%	2,264	7.5%
Inflammatory adenocarcinoma (8530)	1,003	0.3%	780	0.3%	159	0.5%	52	0.2%	-	-	140	0.5%
Infiltrating duct mixed and infiltrating lobular mixed (8522-8524)	27,371	9.3%	22,952	9.7%	2,372	7.4%	1,762	7.7%	84	6.9%	2,892	9.6%
Mucinous adenocarcinoma (8480,8482)	5,737	1.9%	4,469	1.9%	624	2.0%	563	2.5%	24	2.0%	532	1.8%
Mucin-producing adenocarcinoma (8481)	68	0.0%	48	0.0%	-	-	-	-	-	-	-	-
Tubular adenocarcinoma (8211)	1,850	0.6%	1,636	0.7%	110	0.3%	92	0.4%	-	-	143	0.5%
Papillary adenocarcinoma (8050,8260,8503,8504)	1,754	0.6%	1,252	0.5%	288	0.9%	190	0.8%	-	-	187	0.6%
Paget disease (8540-8543)	1,259	0.4%	998	0.4%	132	0.4%	107	0.5%	-	-	146	0.5%
Other adenocarcinomas ^f	3,336	1.1%	2,612	1.1%	399	1.2%	262	1.1%	-	-	339	1.1%
Other specific carcinomas ^g	2,415	0.8%	1,797	0.8%	455	1.4%	136	0.6%	-	-	288	1.0%
Medullary adenocarcinoma (8510-8513)	815	0.3%	549	0.2%	212	0.7%	46	0.2%	-	-	136	0.5%
Other ^h	1,600	0.5%	1,248	0.5%	243	0.8%	90	0.4%	-	-	152	0.5%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	3,356	1.1%	2,587	1.1%	496	1.6%	193	0.8%	-	-	324	1.1%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f Adenocarcinoma includes histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^g Other adenocarcinomas include histologies 8141-8147, 8160-8162, 8180-8210, 8212-8221, 8250-8259, 8261-8479, 8483-8499, 8501-8502, 8505-8507, 8514, 8521, 8525-8529, 8531-8539, 8544-8551, 8560, 8570-8574, 8576, 8940-8941.

^h Other specific carcinomas include histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

ⁱ Other includes histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8249, 8508, 8561-8562, 8575, 8580-8671.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 4.25 - continued

Cancer of the Female Breast (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2008-2012
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 9040-9044,9120-9136, 9150-9252,9370-9373, 9540-9582)	325	0.1%	243	0.1%	46	0.1%	31	0.1%	-	-	25	0.1%
Hemangiosarcomas (9120-9126,9170)	157	0.1%	133	0.1%	-	-	-	-	-	-	-	-
Other sarcomas ^d	168	0.1%	110	0.0%	37	0.1%	18	0.1%	-	-	19	0.1%
Other specific types (8720-8790,8930-8936, 8950-9030,9060-9110, 9260-9365,9380-9539)	741	0.3%	532	0.2%	89	0.3%	109	0.5%	-	-	122	0.4%
Phyllodes tumor, malignant (9020)	622	0.2%	442	0.2%	69	0.2%	101	0.4%	-	-	106	0.4%
Other ^e	119	0.0%	90	0.0%	20	0.1%	-	-	-	-	16	0.1%
Unspecified (8000-8005)	657	0.2%	495	0.2%	90	0.3%	41	0.2%	-	-	70	0.2%
Total ^f	295,023	100.0%	236,244	100.0%	31,998	100.0%	22,923	100.0%	1,216	100.0%	30,170	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Other sarcomas include histologies 8680-8713, 8800-8921, 9040-9044, 9127-9136, 9150-9169, 9171-9252, 9370-9373, 9540-9582.

^e Other includes histologies 8720-8790, 8930-8936, 8950-9019, 9021-9030, 9060-9110, 9260-9365, 9380-9539.

^f Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 4.26

Cancer of the Female Breast(In Situ)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2008-2012
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Adenocarcinoma ^d	75,183	99.8%	58,643	99.8%	8,059	99.8%	7,338	100.0%	246	100.0%	7,005	99.8%
Adenocarcinoma <i>in situ</i> , NOS (8140/2)	-	-	-	-	-	-	-	-	-	-	-	-
Ductal carcinoma <i>in situ</i> ^e	63,846	84.8%	49,203	83.7%	7,070	87.5%	6,658	90.7%	215	87.4%	6,014	85.7%
Cribriform carcinoma <i>in situ</i> (8201/2)	6,409	8.5%	4,826	8.2%	748	9.3%	735	10.0%	21	8.5%	615	8.8%
Ductal carcinoma <i>in situ</i> , solid type(8230/2)	5,073	6.7%	4,042	6.9%	477	5.9%	479	6.5%	18	7.3%	419	6.0%
Ductal carcinoma <i>in situ</i> , NOS (8500/2)	22,740	30.2%	17,793	30.3%	2,508	31.0%	2,074	28.3%	78	31.7%	2,106	30.0%
Comedocarcinoma <i>in situ</i> (8501/2)	6,030	8.0%	4,689	8.0%	614	7.6%	641	8.7%	34	13.8%	562	8.0%
Ductal carcinoma <i>in situ</i> papillary(8503/2)	1,156	1.5%	790	1.3%	202	2.5%	142	1.9%	-	-	114	1.6%
Noninfiltrating intracystic carcinoma(8504/2)	264	0.4%	171	0.3%	38	0.5%	52	0.7%	-	-	27	0.4%
Ductal carcinoma <i>in situ</i> micropapillary(8507/2)	1,352	1.8%	1,064	1.8%	168	2.1%	105	1.4%	-	-	130	1.9%
Intraductal with other types of carcinoma <i>in situ</i> (8523/2)	20,649	27.4%	15,703	26.7%	2,305	28.5%	2,395	32.6%	58	23.6%	2,028	28.9%
Lobular carcinoma <i>in situ</i> (8520/2-8521/2, 8524/2)	8,560	11.4%	7,239	12.3%	686	8.5%	441	6.0%	26	10.6%	755	10.8%
Lobular carcinoma <i>in situ</i> , NOS (8520/2)	8,538	11.3%	7,220	12.3%	683	8.5%	441	6.0%	26	10.6%	754	10.7%
Lobular CIS ^f with other CIS ^f (8524/2)	22	0.0%	19	0.0%	-	-	-	-	-	-	-	-
Intraductal and lobular <i>in situ</i> carcinoma (8522/2)	2,261	3.0%	1,819	3.1%	239	3.0%	175	2.4%	-	-	188	2.7%
Other adenocarcinomas ^g	510	0.7%	378	0.6%	64	0.8%	62	0.8%	-	-	48	0.7%
Other <i>in situ</i> histologies ^h	137	0.2%	108	0.2%	20	0.2%	-	-	-	-	-	-
Total	75,320	100.0%	58,751	100.0%	8,079	100.0%	7,341	100.0%	246	100.0%	7,018	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8230,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.

^f Ductal carcinoma includes histologies 8201, 8230, 8401, 8500-8507, 8523.

^g CIS = Carcinoma *in situ*.

^h Other adenocarcinomas include 8050, 8141-8147, 8160-8162, 8180-8200, 8202-8221, 8250-8400, 8402-8499, 8514, 8525-8551, 8560, 8570-8574, 8576, 8940-8941.

ⁱ Other histologies include 8000-8049, 8051-8139, 8148-8159, 8163-8179, 8222-8229, 8231-8249, 8508-8513, 8515-8519, 8552-8559, 8561-8569, 8575, 8577-8939, 8942-9989.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 5.16

Cancer of the Cervix Uteri (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2008-2012
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	16,473	98.1%	12,363	98.3%	2,317	97.6%	1,447	98.2%	122	97.6%	3,634	98.2%
Epidermoid carcinoma ^d (8050-8131)	11,051	65.8%	8,034	63.9%	1,818	76.6%	965	65.5%	75	60.0%	2,483	67.1%
Squamous cell carcinoma (8070)	7,658	45.6%	5,509	43.8%	1,317	55.5%	665	45.1%	57	45.6%	1,563	42.3%
Squamous cell, keratinizing (8071)	1,152	6.9%	833	6.6%	197	8.3%	101	6.9%	-	-	305	8.2%
Squamous cell, non-keratinizing (8072)	1,493	8.9%	1,132	9.0%	202	8.5%	136	9.2%	-	-	427	11.5%
Squamous cell, Microinvasive (8076)	499	3.0%	376	3.0%	61	2.6%	42	2.9%	-	-	131	3.5%
Other (8050-8069, 8073-8075,8077-8131)	249	1.5%	184	1.5%	41	1.7%	21	1.4%	-	-	57	1.5%
Adenocarcinoma ^e	4,699	28.0%	3,800	30.2%	380	16.0%	429	29.1%	37	29.6%	987	26.7%
Adenocarcinoma, NOS (8140)	2,511	15.0%	2,042	16.2%	198	8.3%	220	14.9%	17	13.6%	538	14.5%
Adenosquamous (8560,8570)	565	3.4%	439	3.5%	59	2.5%	60	4.1%	-	-	128	3.5%
Other adenocarcinomas ^f	1,623	9.7%	1,319	10.5%	123	5.2%	149	10.1%	-	-	321	8.7%
Other specific carcinomas ^g	264	1.6%	209	1.7%	33	1.4%	19	1.3%	-	-	57	1.5%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	459	2.7%	320	2.5%	86	3.6%	34	2.3%	-	-	107	2.9%
Sarcoma ^h	61	0.4%	42	0.3%	-	-	-	-	-	-	-	-
Other specific types (8720-8790,8930-8936, 8950-9030,9060-9110, 9260-9365,9380-9539)	162	1.0%	107	0.9%	30	1.3%	17	1.2%	-	-	32	0.9%
Unspecified (8000-8005)	89	0.5%	65	0.5%	-	-	-	-	-	-	20	0.5%
Total	16,785	100.0%	12,577	100.0%	2,373	100.0%	1,473	100.0%	125	100.0%	3,699	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^e Adenocarcinoma includes histologies 8140-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.

^f Other adenocarcinomas include histologies 8141-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8571-8574,8576,8940-8941.

^g Other specific carcinomas include histologies 8012-8015,8030-8046,8150-8155,8170-8175,8230-8249,8508,8510-8513,8561-8562,8575,8580-8671.

^h Sarcoma includes histologies 8680-8713,8800-8921,9040-9044,9120-9136,9150-9252,9370-9373,9540-9582.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 6.29

Cancer of the Colon And Rectum (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2008-2012
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	180,720	99.4%	141,644	99.5%	21,747	99.4%	14,393	99.4%	976	99.7%	18,469	99.4%
Epidermoid carcinoma ^d (8051-8131)	1,113	0.6%	942	0.7%	130	0.6%	21	0.1%	-	-	96	0.5%
Squamous cell carcinoma (8070-8078,8083-8084)	1,054	0.6%	893	0.6%	125	0.6%	21	0.1%	-	-	90	0.5%
Adenocarcinoma (8050,8140-8147, 8160-8162,8180-8221, 8250-8507,8520-8551,8560, 8570-8574,8576,8940-8941)	169,224	93.1%	133,801	94.0%	19,702	90.1%	13,345	92.2%	905	92.4%	17,173	92.4%
Adenocarcinoma, NOS (8140)	116,238	63.9%	91,560	64.3%	13,674	62.5%	9,533	65.8%	660	67.4%	11,872	63.9%
Adenocarcinoma in adenomatous polyp (8210)	15,009	8.3%	11,773	8.3%	1,624	7.4%	1,283	8.9%	85	8.7%	1,345	7.2%
Adenocarcinoma in villous adenoma (8261)	4,443	2.4%	3,585	2.5%	464	2.1%	330	2.3%	18	1.8%	575	3.1%
Mucinous adenocarcinoma (8470-8473,8480,8482)	11,678	6.4%	9,649	6.8%	1,221	5.6%	698	4.8%	53	5.4%	1,269	6.8%
Mucin-producing adenocarcinoma (8481)	1,855	1.0%	1,502	1.1%	253	1.2%	93	0.6%	-	-	172	0.9%
Signet ring adenocarcinoma (8490)	2,039	1.1%	1,675	1.2%	197	0.9%	144	1.0%	-	-	214	1.2%
Other adenocarcinomas ^e	17,962	9.9%	14,057	9.9%	2,269	10.4%	1,264	8.7%	78	8.0%	1,726	9.3%
Other specific carcinomas (8012-8015,8030-8046, 8150-8155,8170-8175, 8230-8249,8508,8510-8513, 8561-8562,8575,8580-8671)	8,787	4.8%	5,665	4.0%	1,711	7.8%	914	6.3%	50	5.1%	1,033	5.6%
Neuroendocrine carcinoid (8240-8245)	6,693	3.7%	4,080	2.9%	1,409	6.4%	758	5.2%	42	4.3%	842	4.5%
Other ^f	2,094	1.2%	1,585	1.1%	302	1.4%	156	1.1%	-	-	191	1.0%
Unspecified, Carcinoma, NOS (8010-8011, 8020-8022)	1,596	0.9%	1,236	0.9%	204	0.9%	113	0.8%	19	1.9%	167	0.9%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f Includes histologies 8050, 8141-8147, 8160-8162, 8180-8204, 8211-8221, 8250-8260, 8262-8264, 8270-8463, 8500-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^f Includes histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8231, 8246-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 6.29 - continued

Cancer of the Colon And Rectum (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2008-2012
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9150-9252, 9370-9373,9540-9582)	110	0.1%	89	0.1%	-	-	-	-	-	-	16	0.1%
Other specific types (8720-8790,8930-8936, 8950-8983,9000-9030, 9060-9110,9260-9365, 9380-9539)	293	0.2%	202	0.1%	45	0.2%	44	0.3%	-	-	32	0.2%
Unspecified (8000-8005)	648	0.4%	480	0.3%	61	0.3%	40	0.3%	-	-	66	0.4%
Total ^d	181,771	100.0%	142,415	100.0%	21,868	100.0%	14,481	100.0%	979	100.0%	18,583	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 8.22

Cancer of the Esophagus (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2008-2012
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	18,629	99.0%	15,657	99.0%	1,957	99.2%	822	99.0%	78	100.0%	1,392	98.8%
Epidermoid carcinoma ^d (8051-8131)	6,214	33.0%	4,016	25.4%	1,571	79.7%	567	68.3%	26	33.3%	509	36.1%
Squamous cell carcinoma (8070-8078, 8083-8084)	6,195	32.9%	4,003	25.3%	1,565	79.4%	567	68.3%	26	33.3%	508	36.1%
Adenocarcinoma ^e	11,565	61.5%	10,912	69.0%	313	15.9%	221	26.6%	47	60.3%	818	58.1%
Other specific carcinomas ^f	282	1.5%	235	1.5%	31	1.6%	-	-	-	-	20	1.4%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	568	3.0%	494	3.1%	42	2.1%	22	2.7%	-	-	45	3.2%
Other specific types ^g	59	0.3%	50	0.3%	-	-	-	-	-	-	-	-
Unspecified (8000-8005)	121	0.6%	103	0.7%	-	-	-	-	-	-	-	-
Total	18,809	100.0%	15,810	100.0%	1,972	100.0%	830	100.0%	78	100.0%	1,409	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f Adenocarcinoma is defined as histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^g Other specific carcinomas is defined as histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

^h Other specific types includes sarcomas and other soft tissue tumors.

ⁱ Other specific types is defined as histologies 8680-8713, 8720-8790, 8800-8921, 8930-8936, 8950-9030, 9040-9044, 9060-9110, 9120-9136, 9150-9252, 9260-9365, 9370-9373, 9380-9539, 9540-9582.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 14.22

Cancer of the Liver and Intrahepatic Bile Duct (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2008-2012
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma (8010-8576)	22,463	97.1%	15,854	96.9%	2,909	98.1%	3,327	97.7%	203	97.6%	3,702	95.2%
Hepatocellular carcinoma ^d (8170-8175)	17,223	74.5%	11,792	72.1%	2,449	82.6%	2,680	78.7%	160	76.9%	2,920	75.1%
Cholangiocarcinoma (8032-8033,8070-8071, 8140-8141,8160,8260, 8480-8481,8490,8560)	4,252	18.4%	3,341	20.4%	344	11.6%	512	15.0%	35	16.8%	613	15.8%
Other carcinoma ^e	988	4.3%	721	4.4%	116	3.9%	135	4.0%	-	-	169	4.3%
Other specific carcinoma ^f	614	2.7%	453	2.8%	68	2.3%	86	2.5%	-	-	105	2.7%
Unspecified, Carcinoma, NOS (8010,8020-8022,8031, 8046,8050)	374	1.6%	268	1.6%	48	1.6%	49	1.4%	-	-	64	1.6%
Hepatoblastoma (8970)	229	1.0%	172	1.1%	19	0.6%	29	0.9%	-	-	83	2.1%
Sarcoma ^g	219	0.9%	174	1.1%	18	0.6%	24	0.7%	-	-	43	1.1%
Hemangiosarcoma (9120)	86	0.4%	68	0.4%	-	-	-	-	-	-	17	0.4%
Other sarcomas ^h	133	0.6%	106	0.6%	-	-	-	-	-	-	26	0.7%
Other specific types (8720,8980,8991,9061, 9064,9070-9071,9080, 9100)	41	0.2%	31	0.2%	-	-	-	-	-	-	-	-
Unspecified (8000-8004)	169	0.7%	133	0.8%	-	-	21	0.6%	-	-	45	1.2%
Total ^d	23,123	100.0%	16,366	100.0%	2,965	100.0%	3,406	100.0%	208	100.0%	3,887	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percentages may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma arising from liver parenchyma are referred to as hepatocellular carcinoma.

^f Other carcinoma include histologies 8010, 8012-8013, 8020-8022, 8031, 8035, 8041-8042, 8046, 8050, 8124, 8142, 8154, 8161-8162, 8180, 8190, 8211, 8240, 8246, 8249, 8255, 8290, 8310, 8323, 8337, 8440, 8450, 8453, 8470-8471, 8500, 8503, 8510, 8521, 8550, 8574, 8576.

^g Other specific carcinoma include histologies 8012-8013, 8035, 8041-8042, 8124, 8142, 8154, 8161-8162, 8180, 8190, 8211, 8240, 8246, 8249, 8255, 8290, 8310, 8323, 8337, 8440, 8450, 8453, 8470-8471, 8500, 8503, 8510, 8521, 8550, 8574, 8576.

^h Sarcoma includes histologies 8800-8806, 8810, 8815, 8830, 8850, 8852, 8854, 8890-8891, 8894-8896, 8900, 8910, 8920, 8935-8936, 8940, 8963, 8990, 9040-9041, 9044, 9120, 9124, 9130, 9133, 9150, 9180, 9220, 9260, 9364, 9473, 9500, 9540, 9560, 9581.

ⁱ Other sarcomas include histologies 8800-8806, 8810, 8815, 8830, 8850, 8852, 8854, 8890-8891, 8894-8896, 8900, 8910, 8920, 8935-8936, 8940, 8963, 8990, 9040-9041, 9044, 9124, 9130, 9133, 9150, 9180, 9220, 9260, 9364, 9473, 9500, 9540, 9560, 9581.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 15.28

Cancer of the Lung and Bronchus (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2008-2012
Both Sexes by Race

Histology ^a	All Races			White		Black		Asian/Pacific Islander		American Indian/Alaska Native ^b		Hispanic ^c	
	Rate	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	51.9	226,896	99.7%	186,528	99.7%	25,544	99.7%	13,248	99.7%	774	99.1%	12,809	99.4%
Small cell (8002,8041-8045)	6.8	30,156	13.3%	26,229	14.0%	2,660	10.4%	1,038	7.8%	141	18.1%	1,430	11.1%
Non-small cell	43.5	189,727	83.4%	154,665	82.7%	21,991	85.8%	11,775	88.6%	608	77.8%	10,843	84.2%
Squamous and transitional cell ^d	11.9	51,375	22.6%	42,831	22.9%	6,133	23.9%	2,059	15.5%	194	24.8%	2,393	18.6%
Adenocarcinoma ^e	22.5	98,473	43.3%	79,151	42.3%	10,976	42.8%	7,720	58.1%	260	33.3%	5,987	46.5%
Large cell ^f	1.1	4,672	2.1%	3,817	2.0%	635	2.5%	197	1.5%	-	-	228	1.8%
Non-small cell carcinoma ^g	5.5	23,952	10.5%	19,243	10.3%	3,178	12.4%	1,318	9.9%	118	15.1%	1,375	10.7%
Other specified carcinomas ^h	2.6	11,255	4.9%	9,623	5.1%	1,069	4.2%	481	3.6%	25	3.2%	860	6.7%
Carcinoma, NOS ⁱ	1.6	7,013	3.1%	5,634	3.0%	893	3.5%	435	3.3%	25	3.2%	536	4.2%
Sarcoma ^j	0.1	433	0.2%	353	0.2%	47	0.2%	24	0.2%	-	-	52	0.4%
Other specified types ^k	0.0	198	0.1%	160	0.1%	27	0.1%	-	-	-	-	22	0.2%
Total	52.0	227,527	100.0%	187,041	100.0%	25,618	100.0%	13,283	100.0%	781	100.0%	12,883	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percentages may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Squamous and transitional cell includes histologies 8051-8052, 8070-8076, 8078, 8083-8084, 8090, 8094, 8120, 8123.

^e Adenocarcinoma includes histologies 8015, 8050, 8140-8141, 8143-8145, 8147, 8190, 8201, 8211, 8250-8255, 8260, 8290, 8310, 8320, 8323, 8333, 8401, 8440, 8470-8471, 8480-8481, 8490, 8503, 8507, 8550, 8570-8572, 8574, 8576.

^f Large cell includes histologies 8012-8014, 8021, 8034, 8082.

^g Non-small cell carcinoma includes histology 8046.

^h Other specified carcinomas includes histologies 8003-8004, 8022, 8030, 8031-8033, 8035, 8200, 8240-8241, 8243-8246, 8249, 8430, 8525, 8560, 8562, 8575.

ⁱ Carcinoma, NOS includes histologies 8000-8001, 8010-8011, 8020, 8230.

^j Sarcoma includes histologies 8680, 8711, 8800-8805, 8810-8811, 8815, 8824, 8830, 8840, 8852, 8855, 8890-8891, 8894-8895, 8900-8902, 8910, 8920-8921, 8940, 8990, 9040-9041, 9043, 9120, 9130, 9133, 9150, 9180, 9220, 9231, 9240, 9251, 9473, 9540, 9560, 9580.

^k Other specific types includes melanomas and is defined as histologies 8580, 8650, 8720-8790, 8933, 8963, 8972-8973, 8980-8982, 9064-9065, 9070, 9080, 9084-9085, 9100, 9260, 9364, 9503, 9530.

Note: For this analysis, the following histologies were classified as metastases of another primary site and not included: 8005, 8130, 8146, 8170, 8231, 8247, 8263, 8312, 8340-8341, 8350, 8441, 8460, 8500-8501, 8524, 8530, 8551, 8581, 8585, 8710, 8772, 8806, 8850, 8854, 8896, 8935, 9015, 9042, 9071, 9101, 9181, 9370, 9500, 9561, 9581

- Statistic not shown due to fewer than 16 cases during the time period.

Table 15.29

Cancer of the Lung and Bronchus (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2008-2012
Males by Race

Histology ^a	All Races			White		Black		Asian/Pacific Islander		American Indian/Alaska Native ^b		Hispanic ^c	
	Rate	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	61.7	120,021	99.7%	97,398	99.7%	14,323	99.7%	7,457	99.7%	401	99.5%	6,749	99.4%
Small cell (8002,8041-8045)	7.5	15,056	12.5%	12,917	13.2%	1,353	9.4%	682	9.1%	64	15.9%	754	11.1%
Non-small cell	52.1	101,018	83.9%	81,392	83.3%	12,413	86.4%	6,503	87.0%	326	80.9%	5,681	83.6%
Squamous and transitional cell ^d	16.8	32,229	26.8%	26,568	27.2%	3,934	27.4%	1,494	20.0%	117	29.0%	1,514	22.3%
Adenocarcinoma ^e	24.4	47,518	39.5%	37,692	38.6%	5,726	39.9%	3,790	50.7%	125	31.0%	2,827	41.6%
Large cell ^f	1.3	2,631	2.2%	2,125	2.2%	370	2.6%	124	1.7%	-	-	139	2.0%
Non-small cell carcinoma ^g	6.9	13,474	11.2%	10,681	10.9%	1,847	12.9%	829	11.1%	68	16.9%	799	11.8%
Other specified carcinomas ^h	2.6	5,166	4.3%	4,326	4.4%	536	3.7%	266	3.6%	-	-	402	5.9%
Carcinoma, NOS ⁱ	2.1	3,947	3.3%	3,089	3.2%	557	3.9%	272	3.6%	-	-	314	4.6%
Sarcoma ^j	0.1	239	0.2%	200	0.2%	25	0.2%	-	-	-	-	28	0.4%
Other specified types ^k	0.1	126	0.1%	105	0.1%	-	-	-	-	-	-	-	-
Total	61.9	120,386	100.0%	97,703	100.0%	14,361	100.0%	7,476	100.0%	403	100.0%	6,792	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percentages may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Squamous and transitional cell includes histologies 8051-8052, 8070-8076, 8078, 8083-8084, 8090, 8094, 8120, 8123.

^e Adenocarcinoma includes histologies 8015, 8050, 8140-8141, 8143-8145, 8147, 8190, 8201, 8211, 8250-8255, 8260, 8290, 8310, 8320, 8323, 8333, 8401, 8440, 8470-8471, 8480-8481, 8490, 8503, 8507, 8550, 8570-8572, 8574, 8576.

^f Large cell includes histologies 8012-8014, 8021, 8034, 8082.

^g Non-small cell carcinoma includes histology 8046.

^h Other specified carcinomas includes histologies 8003-8004, 8022, 8030, 8031-8033, 8035, 8200, 8240-8241, 8243-8246, 8249, 8430, 8525, 8560, 8562, 8575.

ⁱ Carcinoma, NOS includes histologies 8000-8001, 8010-8011, 8020, 8230.

^j Sarcoma includes histologies 8680, 8711, 8800-8805, 8810-8811, 8815, 8824, 8830, 8840, 8852, 8855, 8890-8891, 8894-8895, 8900-8902, 8910, 8920-8921, 8940, 8990, 9040-9041, 9043, 9120, 9130, 9133, 9150, 9180, 9220, 9231, 9240, 9251, 9473, 9540, 9560, 9580.

^k Other specific types includes melanomas and is defined as histologies 8580, 8650, 8720-8790, 8933, 8963, 8972-8973, 8980-8982, 9064-9065, 9070, 9080, 9084-9085, 9100, 9260, 9364, 9503, 9530.

Note: For this analysis, the following histologies were classified as metastases of another primary site and not included: 8005, 8130, 8146, 8170, 8231, 8247, 8263, 8312, 8340-8341, 8350, 8441, 8460, 8500-8501, 8524, 8530, 8551, 8581, 8585, 8710, 8772, 8806, 8850, 8854, 8896, 8935, 9015, 9042, 9071, 9101, 9181, 9370, 9500, 9561, 9581

- Statistic not shown due to fewer than 16 cases during the time period.

Table 15.30

Cancer of the Lung and Bronchus (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2008-2012
Females by Race

Histology ^a	All Races			White		Black		Asian/Pacific Islander		American Indian/Alaska Native ^b		Hispanic ^c	
	Rate	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	44.5	106,875	99.8%	89,130	99.8%	11,221	99.7%	5,791	99.7%	373	98.7%	6,060	99.5%
Small cell (8002,8041-8045)	6.2	15,100	14.1%	13,312	14.9%	1,307	11.6%	356	6.1%	77	20.4%	676	11.1%
Non-small cell	37.0	88,709	82.8%	73,273	82.0%	9,578	85.1%	5,272	90.8%	282	74.6%	5,162	84.7%
Squamous and transitional cell ^d	8.1	19,146	17.9%	16,263	18.2%	2,199	19.5%	565	9.7%	77	20.4%	879	14.4%
Adenocarcinoma ^e	21.2	50,955	47.6%	41,459	46.4%	5,250	46.6%	3,930	67.7%	135	35.7%	3,160	51.9%
Large cell ^f	0.8	2,041	1.9%	1,692	1.9%	265	2.4%	73	1.3%	-	-	89	1.5%
Non-small cell carcinoma ^g	4.4	10,478	9.8%	8,562	9.6%	1,331	11.8%	489	8.4%	50	13.2%	576	9.5%
Other specified carcinomas ^h	2.6	6,089	5.7%	5,297	5.9%	533	4.7%	215	3.7%	-	-	458	7.5%
Carcinoma, NOS ⁱ	1.3	3,066	2.9%	2,545	2.8%	336	3.0%	163	2.8%	-	-	222	3.6%
Sarcoma ^j	0.1	194	0.2%	153	0.2%	22	0.2%	-	-	-	-	24	0.4%
Other specified types ^k	0.0	72	0.1%	55	0.1%	-	-	-	-	-	-	-	-
Total	44.6	107,141	100.0%	89,338	100.0%	11,257	100.0%	5,807	100.0%	378	100.0%	6,091	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percentages may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Squamous and transitional cell includes histologies 8051-8052, 8070-8076, 8078, 8083-8084, 8090, 8094, 8120, 8123.

^e Adenocarcinoma includes histologies 8015, 8050, 8140-8141, 8143-8145, 8147, 8190, 8201, 8211, 8250-8255, 8260, 8290, 8310, 8320, 8323, 8333, 8401, 8440, 8470-8471, 8480-8481, 8490, 8503, 8507, 8550, 8570-8572, 8574, 8576.

^f Large cell includes histologies 8012-8014, 8021, 8034, 8082.

^g Non-small cell carcinoma includes histology 8046.

^h Other specified carcinomas includes histologies 8003-8004, 8022, 8030, 8031-8033, 8035, 8200, 8240-8241, 8243-8246, 8249, 8430, 8525, 8560, 8562, 8575.

ⁱ Carcinoma, NOS includes histologies 8000-8001, 8010-8011, 8020, 8230.

^j Sarcoma includes histologies 8680, 8711, 8800-8805, 8810-8811, 8815, 8824, 8830, 8840, 8852, 8855, 8890-8891, 8894-8895, 8900-8902, 8910, 8920-8921, 8940, 8990, 9040-9041, 9043, 9120, 9130, 9133, 9150, 9180, 9220, 9231, 9240, 9251, 9473, 9540, 9560, 9580.

^k Other specific types includes melanomas and is defined as histologies 8580, 8650, 8720-8790, 8933, 8963, 8972-8973, 8980-8982, 9064-9065, 9070, 9080, 9084-9085, 9100, 9260, 9364, 9503, 9530.

Note: For this analysis, the following histologies were classified as metastases of another primary site and not included: 8005, 8130, 8146, 8170, 8231, 8247, 8263, 8312, 8340-8341, 8350, 8441, 8460, 8500-8501, 8524, 8530, 8551, 8581, 8585, 8710, 8772, 8806, 8850, 8854, 8896, 8935, 9015, 9042, 9071, 9101, 9181, 9370, 9500, 9561, 9581

- Statistic not shown due to fewer than 16 cases during the time period.

Table 20.28

Cancer of the Oral Cavity and Pharynx (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2008-2012
All Races, Both Sexes, by site

Histology ^a	Oral Cavity and Pharynx		Lip		Tongue		Salivary Gland		Floor of Mouth	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Epidermoid carcinoma ^b (8051-8131)	41,634	84.3%	2,759	94.4%	14,414	97.3%	1,212	21.9%	2,411	95.4%
Squamous cell carcinoma (8070-8078,8083-8084)	40,643	82.3%	2,645	90.5%	14,168	95.6%	1,160	20.9%	2,385	94.4%
Adenocarcinoma ^c	5,033	10.2%	116	4.0%	223	1.5%	3,392	61.2%	83	3.3%
Other specific carcinomas ^d	514	1.0%	-	-	37	0.2%	306	5.5%	-	-
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	1,611	3.3%	-	-	79	0.5%	414	7.5%	-	-
Sarcoma and soft tissue ^e	153	0.3%	-	-	19	0.1%	33	0.6%	-	-
Other specific types ^f	264	0.5%	17	0.6%	16	0.1%	115	2.1%	-	-
Unspecified (8000-8005)	183	0.4%	-	-	33	0.2%	70	1.3%	-	-
Total	49,393	100.0%	2,923	100.0%	14,821	100.0%	5,542	100.0%	2,526	100.0%

Histology ^a	Gum and Other Mouth		Nasopharynx		Oropharynx and Tonsil		Hypopharynx		Other Oral Cavity and Pharynx	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Epidermoid carcinoma ^b (8051-8131)	5,360	80.9%	1,717	62.4%	10,307	97.5%	2,712	96.9%	742	89.1%
Squamous cell carcinoma (8070-8078,8083-8084)	5,111	77.1%	1,566	56.9%	10,185	96.4%	2,691	96.1%	732	87.9%
Adenocarcinoma ^c	1,034	15.6%	87	3.2%	64	0.6%	16	0.6%	18	2.2%
Other specific carcinomas ^d	42	0.6%	39	1.4%	41	0.4%	21	0.8%	-	-
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	57	0.9%	843	30.6%	121	1.1%	35	1.3%	35	4.2%
Sarcoma and soft tissue ^e	31	0.5%	34	1.2%	-	-	-	-	-	-
Other specific types ^f	86	1.3%	16	0.6%	-	-	-	-	-	-
Unspecified (8000-8005)	17	0.3%	17	0.6%	20	0.2%	-	-	-	-
Total	6,628	100.0%	2,753	100.0%	10,568	100.0%	2,799	100.0%	833	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^c Adenocarcinoma includes histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^d Other specific carcinomas includes histologies 8012-8015, 8030-8046, 8150-8155, 8170-8180, 8230-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

^e Sarcoma and soft tissue includes histologies 8680-8713, 8800-8921, 8990-8991, 9040-9044, 9120-9136, 9150-9252, 9370-9373, 9540-9582.

^f Other specific types includes histologies 8720-8790, 8930-8936, 8950-8983, 9060-9110, 9260-9365, 9380-9539.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 21.16

Cancer of the Ovary (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2008-2012
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	24,670	91.6%	20,525	92.2%	1,973	87.8%	1,909	90.6%	124	92.5%	3,009	87.2%
Epidermoid carcinoma ^d (8051-8131)	202	0.8%	157	0.7%	20	0.9%	22	1.0%	-	-	34	1.0%
Adenocarcinoma ^e	22,644	84.1%	18,937	85.0%	1,713	76.2%	1,765	83.8%	111	82.8%	2,711	78.5%
Adenocarcinoma, NOS (8140)	3,108	11.5%	2,515	11.3%	399	17.8%	169	8.0%	-	-	318	9.2%
Papillary adenocarcinoma, NOS (8050,8260)	357	1.3%	304	1.4%	34	1.5%	-	-	-	-	48	1.4%
Clear cell adenocarcinoma (8310,9110)	1,434	5.3%	1,098	4.9%	60	2.7%	264	12.5%	-	-	161	4.7%
Endometrioid carcinoma (8380-8383,8570)	2,640	9.8%	2,201	9.9%	131	5.8%	277	13.1%	-	-	401	11.6%
Cystadenocarcinoma, NOS (8440,8450)	98	0.4%	80	0.4%	-	-	-	-	-	-	17	0.5%
Serous cystadenocarcinoma (8441)	6,303	23.4%	5,388	24.2%	433	19.3%	409	19.4%	41	30.6%	663	19.2%
Papillary serous cystadenocarcinoma (8460-8462)	5,863	21.8%	5,019	22.5%	452	20.1%	347	16.5%	26	19.4%	712	20.6%
Mucinous cystadenocarcinoma (8470-8473)	389	1.4%	315	1.4%	27	1.2%	43	2.0%	-	-	60	1.7%
Mucinous adenocarcinoma (8480,8482)	984	3.7%	779	3.5%	84	3.7%	107	5.1%	-	-	148	4.3%
Mucin-producing adenocarcinoma(8481)	41	0.2%	33	0.1%	-	-	-	-	-	-	-	-
Other adenocarcinoma ^f	1,427	5.3%	1,205	5.4%	77	3.4%	127	6.0%	-	-	179	5.2%
Other specific carcinomas ^g	640	2.4%	454	2.0%	128	5.7%	45	2.1%	-	-	100	2.9%
Stromal cell tumor (8620-8631,8650)	451	1.7%	304	1.4%	105	4.7%	30	1.4%	-	-	70	2.0%
Other ^h	189	0.7%	150	0.7%	23	1.0%	-	-	-	-	30	0.9%
Unspecified, Carcinoma, NOS (8010,8020-8022)	1,184	4.4%	977	4.4%	112	5.0%	77	3.7%	-	-	164	4.8%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).
Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941,9110.

^g Other adenocarcinoma includes histologies 8141-8147,8160-8162,8180-8221,8250-8259,8261-8309,8311-8379,8384-8439,8442-8449,8451-8459,8463-8469,8474-8479,8483-8507,8514,8520-8551,8560,8571-8574,8576,8940-8941.

^h Other specific carcinomas includes histologies 8011-8015,8030-8046,8150-8155,8170-8175,8230-8231,8247-8249,8508,8510-8513,8561-8562,8575,8580-8671.

ⁱ Other subgroup of other specific carcinomas includes histologies 8011-8015,8030-8046,8150-8155,8170-8175,8230-8231,8247-8249,8508,8510-8513,8561-8562,8575,8580-8619,8632-8649,8651-8671.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 21.16 - continued

Cancer of the Ovary (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2008-2012
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9141-9340, 9540-9582)	91	0.3%	61	0.3%	20	0.9%	-	-	-	-	20	0.6%
Other specific types (8240-8246,8720-8790, 8930-8936,8950-8983, 9000-9030,9060-9105, 9350-9364,9380-9513, 9530-9539)	1,874	7.0%	1,453	6.5%	222	9.9%	167	7.9%	-	-	381	11.0%
Mullerian mixed tumor (8950-8951,8980)	813	3.0%	684	3.1%	74	3.3%	45	2.1%	-	-	80	2.3%
Teratoma, malignant (9080-9085,9102)	415	1.5%	286	1.3%	64	2.8%	55	2.6%	-	-	148	4.3%
Other	646	2.4%	483	2.2%	84	3.7%	67	3.2%	-	-	153	4.4%
Unspecified (8000-8005)	293	1.1%	233	1.0%	32	1.4%	22	1.0%	-	-	42	1.2%
Total ^d	26,928	100.0%	22,272	100.0%	2,247	100.0%	2,107	100.0%	134	100.0%	3,452	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 22.22

Cancer of the Pancreas (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2008-2012
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	43,224	98.0%	34,469	98.0%	5,307	98.0%	3,085	98.1%	180	98.9%	4,332	97.7%
Epidermoid carcinoma ^d (8051-8131)	107	0.2%	79	0.2%	16	0.3%	-	-	-	-	-	-
Adenocarcinoma ^e	37,839	85.8%	30,239	86.0%	4,597	84.8%	2,691	85.6%	159	87.4%	3,773	85.1%
Adenocarcinoma, NOS (8140)	30,694	69.6%	24,489	69.6%	3,816	70.4%	2,128	67.7%	137	75.3%	3,069	69.2%
Papillary adenocarcinoma, NOS (8260)	43	0.1%	33	0.1%	-	-	-	-	-	-	-	-
Mucinous adenocarcinoma (8480,8482)	1,151	2.6%	920	2.6%	127	2.3%	89	2.8%	-	-	117	2.6%
Mucin-producing adenocarcinoma (8481)	400	0.9%	332	0.9%	44	0.8%	23	0.7%	-	-	37	0.8%
Infiltrating duct carcinoma (8500-8503,8507,8514)	4,392	10.0%	3,541	10.1%	460	8.5%	365	11.6%	-	-	399	9.0%
Other adenocarcinoma ^f	1,159	2.6%	924	2.6%	144	2.7%	82	2.6%	-	-	144	3.2%
Other specific carcinomas ^g	3,115	7.1%	2,488	7.1%	370	6.8%	230	7.3%	-	-	314	7.1%
Islet cell carcinoma (8150-8155)	344	0.8%	291	0.8%	34	0.6%	-	-	-	-	30	0.7%
Other carcinomas ^h	2,771	6.3%	2,197	6.2%	336	6.2%	215	6.8%	-	-	284	6.4%
Unspecified, "Carcinoma, NOS" (8010,8020-8022)	2,164	4.9%	1,664	4.7%	324	6.0%	153	4.9%	-	-	240	5.4%
Sarcoma and other soft tissue tumors ⁱ	33	0.1%	27	0.1%	-	-	-	-	-	-	-	-
Other specific types ^j	40	0.1%	32	0.1%	-	-	-	-	-	-	-	-
Unspecified (8000-8005)	799	1.8%	634	1.8%	101	1.9%	56	1.8%	-	-	91	2.1%
Total	44,098	100.0%	35,163	100.0%	5,418	100.0%	3,144	100.0%	182	100.0%	4,435	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^e Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.

^f Other adenocarcinoma include histologies 8050,8141-8147,8160-8162,8180-8221,8250-8259,8261-8479,8483-8499,8504-8506,8520-8551,8560,8570-8574,8576,8940-8941.

^g Other specific carcinomas include histologies 8012-8015,8030-8046,8150-8155,8170-8180,8230-8249,8508,8510-8513,8561-8562,8575,8580-8671.

^h Other carcinomas include histologies 8012-8015,8030-8046,8170-8180,8230-8249,8508,8510-8513,8561-8562,8575,8580-8671.

ⁱ Sarcoma and other soft tissue tumors include histologies 8680-8713,8800-8921,8990-8991,9040-9044,9120-9136,9150-9252,9370-9373,9540-9582.

^j Other specific types include histologies 8720-8790,8930-8936,8950-9030,9060-9110,9260-9365,9380-9539.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 24.22

Cancer of the Stomach (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2008-2012
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	29,238	92.7%	20,894	93.3%	3,862	88.4%	4,041	94.0%	209	95.0%	5,298	95.6%
Epidermoid carcinoma ^d (8051-8131)	280	0.9%	197	0.9%	51	1.2%	27	0.6%	-	-	26	0.5%
Squamous cell carcinoma (8070-8078,8083-8084)	271	0.9%	191	0.9%	50	1.1%	25	0.6%	-	-	23	0.4%
Adenocarcinoma (8050,8140-8147, 8160-8162,8180-8221, 8250-8507,8514,8520-8551, 8560,8570-8574, 8576,8940-8941)	26,161	82.9%	18,578	82.9%	3,409	78.0%	3,828	89.1%	182	82.7%	4,741	85.5%
Adenocarcinoma, NOS (8140)	14,993	47.5%	11,069	49.4%	1,939	44.4%	1,802	41.9%	100	45.5%	2,279	41.1%
Adenocarcinoma, intestinal type (8144)	2,661	8.4%	1,580	7.1%	408	9.3%	634	14.8%	26	11.8%	509	9.2%
Carcinoma, diffuse type (8145)	1,153	3.7%	712	3.2%	143	3.3%	280	6.5%	-	-	259	4.7%
Linitus plastica (8142)	192	0.6%	149	0.7%	20	0.5%	20	0.5%	-	-	53	1.0%
Mucinous adenocarcinoma (8470-8473,8480,8482)	437	1.4%	311	1.4%	63	1.4%	57	1.3%	-	-	72	1.3%
Mucin-producing adenocarcinoma (8481)	150	0.5%	113	0.5%	25	0.6%	-	-	-	-	23	0.4%
Signet ring adenocarcinoma (8490)	5,291	16.8%	3,752	16.7%	659	15.1%	797	18.5%	39	17.7%	1,302	23.5%
Other adenocarcinomas ^e	1,284	4.1%	892	4.0%	152	3.5%	226	5.3%	-	-	244	4.4%
Other specific carcinomas (8012-8015,8030-8046, 8150-8155,8170-8175, 8230-8249,8508,8510-8513, 8561-8562,8575,8580-8671)	2,086	6.6%	1,612	7.2%	296	6.8%	105	2.4%	18	8.2%	421	7.6%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	711	2.3%	507	2.3%	106	2.4%	81	1.9%	-	-	110	2.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^e Other adenocarcinomas includes histologies 8050, 8141, 8143, 8146-8147, 8160-8162, 8180-8221, 8250-8469, 8474-8479, 8483-8489, 8491-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 24.22 - continued

Cancer of the Stomach (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2001-2005
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9150-9252, 9370-9373,9540-9582)	76	0.2%	57	0.3%	-	-	-	-	-	-	-	-
Other specific types (8720-8790,8930-8936, 8950-8983,9000-9030, 9060-9110,9260-9365, 9380-9539)	2,074	6.6%	1,340	6.0%	475	10.9%	237	5.5%	-	-	197	3.6%
Unspecified (8000-8005)	156	0.5%	112	0.5%	21	0.5%	16	0.4%	-	-	36	0.6%
Total ^d	31,544	100.0%	22,403	100.0%	4,371	100.0%	4,298	100.0%	220	100.0%	5,542	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 26.22

Cancer of the Thyroid (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2008-2012
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	58,629	99.7%	47,625	99.7%	3,893	99.5%	5,874	99.7%	260	100.0%	8,784	99.7%
Epidermoid carcinoma ^d (8051-8131)	57	0.1%	43	0.1%	-	-	-	-	-	-	-	-
Adenocarcinoma ^e	56,674	96.3%	46,039	96.4%	3,716	95.0%	5,719	97.1%	253	97.3%	8,510	96.6%
Papillary adenocarcinoma (8050,8260,8340-8344, 8350,8450)	52,060	88.5%	42,415	88.8%	3,200	81.8%	5,345	90.7%	230	88.5%	7,912	89.8%
Follicular carcinoma (8330-8332,8335)	3,011	5.1%	2,303	4.8%	368	9.4%	271	4.6%	-	-	418	4.7%
Oxyphilic (8290)	1,303	2.2%	1,090	2.3%	111	2.8%	77	1.3%	-	-	147	1.7%
Other specific carcinomas ^f	1,055	1.8%	889	1.9%	96	2.5%	50	0.8%	-	-	163	1.8%
Medullary carcinoma (8510)	1,023	1.7%	860	1.8%	93	2.4%	50	0.8%	-	-	159	1.8%
Carcinoma, NOS (8004,8010-8012, 8020-8022,8030-8032)	843	1.4%	654	1.4%	76	1.9%	96	1.6%	-	-	106	1.2%
Anaplastic carcinoma (8004,8012,8020-8021, 8030-8032)	499	0.8%	402	0.8%	40	1.0%	55	0.9%	-	-	63	0.7%
Sarcoma and other soft tissue tumors ^g	-	-	-	-	-	-	-	-	-	-	-	-
Other specific types ^h	-	-	-	-	-	-	-	-	-	-	-	-
Unspecified (8000-8003,8005)	176	0.3%	135	0.3%	16	0.4%	17	0.3%	-	-	25	0.3%
Total	58,828	100.0%	47,779	100.0%	3,913	100.0%	5,891	100.0%	260	100.0%	8,814	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f Adenocarcinoma includes histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^g Other specific carcinomas include histologies 8013-8015, 8033-8046, 8150-8155, 8170-8171, 8230-8249, 8510, 8512, 8561-8562, 8575, 8580-8671.

^h Sarcoma and other soft tissue tumors include histologies 8680-8713, 8800-8921, 8990-8991, 9040-9044, 9120-9136, 9150-9252, 9370-9373, 9540-9582.

ⁱ Other specific types include histologies 8720-8790, 8930-8936, 8950-8983, 9000-9030, 9060-9110, 9260-9365, 9380-9539.

- Statistic not shown due to fewer than 16 cases during the time period.